Payment overview · 2025
General Payments
$190.14
10 reported records · 7 companies
Healthcare provider profile · identity verified
David B Clarke, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANYON, TX · NPI 1245241231
Verified facts
What the public records show
CMS Open Payments records show David B Clarke, MD received $190.14 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.11 | 25.8% | 3 | 2025 |
| INTERNATIONAL REHABILITATIVE SCIENCES, INC | Unresolved — no canonical attribution shown | $37.96 | 20.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.45 | 15.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.73 | 11.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.08 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.15 | 9.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.66 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.14 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RS-4i Plus with Intersperse Normalized: rs 4i plus with intersperse |
Device | INTERNATIONAL REHABILITATIVE SCIENCES, INC | $37.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.90 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 85 |
| Metformin Hcl | Metformin Hcl | 275 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 71 |
| Lisinopril | Lisinopril | 197 | 55 |
| Losartan Potassium | Losartan Potassium | 149 | 41 |
| Alprazolam | Alprazolam | 135 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 32 |
| Gabapentin | Gabapentin | 129 | 43 |
| Indapamide | Indapamide | 99 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 25 |
| Meloxicam | Meloxicam | 93 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 23 |
| Ozempic | Semaglutide | 89 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 88 | 20 |
| Montelukast Sodium | Montelukast Sodium | 88 | 23 |
| Omeprazole | Omeprazole | 87 | 29 |
| Sertraline Hcl | Sertraline Hcl | 84 | 18 |
| Simvastatin | Simvastatin | 81 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Furosemide | Furosemide | 75 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 27 |
| Mounjaro | Tirzepatide | 72 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 29 |
| Tramadol Hcl | Tramadol Hcl | 68 | 20 |
| Carvedilol | Carvedilol | 67 | 16 |
| Telmisartan | Telmisartan | 67 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 24 |
| Trazodone Hcl | Trazodone Hcl | 65 | 17 |
| Np Thyroid | Thyroid,pork | 61 | 22 |
| Ramipril | Ramipril | 61 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 20 |
| Jardiance | Empagliflozin | 56 | suppressed |
| Allopurinol | Allopurinol | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 22 |
| Glimepiride | Glimepiride | 50 | 18 |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Spironolactone | Spironolactone | 49 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 15 |
| Eliquis | Apixaban | 47 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 16 |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Estradiol | Estradiol | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 14 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 12 |
| Anastrozole | Anastrozole | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Famotidine | Famotidine | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.14 · 10 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, RS-4i Plus with Intersperse, TRELEGY ELLIPTA, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error